Written by Dr. Uwe Alschner
Two leading experts in the field of pharmaceutical research and regulatory affairs, Dr. Wolfgang Wodarg from Germany, and Dr. Michael Yeadon from the U.K., have filed a motion with the European Medicines Agency in Amsterdam  to demand a „stay of action“ to the Phase III clinical trials of Pfizer‘s BNT 162b-2 vaccine and „any other ongoing clinical trials of candidates designed to stop transmission, (…) to prevent Covid-19 or mitigate symptoms of Covid-19 for which PCR test results are the primary evidence of infection with SARS-COV-2“.
Wodarg, a former member of the Bundestag (German Parliament), and a medical doctor himself whose special expertise is epidemiology and pulmonology, explained the reasons behind the move in an interview with Del Bigtree on „The Highwire“: „The new vaccines work on a genetically modified basis, that has not been studied long enough to exclude adverse reactions which may be very, very dangerous.“ Dr. Wodarg expressed his gratitude towards scientists in the field who had come forward and raised the alarm about a number of serious concerns. 
Among those concerns is the question of validity of Covid-19 diagnosis which has been raised by a very recent request to retract the scientific blueprint of the PCR-Test that is underlying the global pandemic, the so called Corman-Drosten paper in the Journal Eurosurveillance . This is a concern of both Wodarg as well as Dr. Mike Yeadon, a former chief scientific adviser at Pfizer, who has argued that due to problems with the test, a huge proportion of so called Covid „cases“ might be nothing more but false positive results or, in other words, mis diagnoses. Since even the vaccine trials rely on PCR-Test results to determine the vaccine’s efficacy in preventing transmission (as defined by a PCR-Test) or minimizing symptoms of the disease (as defined by a symptom in combination with a PCR-Test), the concerns of validity of the test need to be addressed before trials can be continued, the petition demands.
Even more serious are major concerns of Antibody Dependend Enhancements (ADEs) which may result in much more severe reactions of a vaccinated individual to the wild virus. ADE-events were observed in animal trials with SARS-coronavirus, as well as with Dengue virus and with RSV in children in the 1960s.
Equally disturbing is the possibility of allergic reactions to the vaccine itself. This may happen due to the detection of polyethylene-glycol (PEG) in the nanoparticle coating around the mRNA. Up to 70percent of people develop antibodies against PEG, which in turn may trigger an allergic reaction upon administration of the vaccine. In addition, the PEG may reduce the vaccines effectiveness altogether, the petition states.
Probably the most disturbing detail of the petition concerns the vaccine strategy of inducing the production of antibodies against the Spike-protein of the virus. This protein has been shown to carry a peptide structure with huge homologous identity to a peptide called Syncytine-1 which is essential to female fertility. Syncytine-1 is said to be derived from Human Endogenous Retroviruses (HERV), which entered the genome of mammals (and thus humans) some 150 million years ago, and led to mammals being able to build a placenta and carry their offspring until birth.
Whilst there is no indication that antibodies against the spike protein of the SARS coronavirus might also act as antibodies against Syncytine-1, the experts demand a halt to the trials, because „it could take a relatively long time before a noticeable number of cases of post-vaccination infertility could be observed.“
If you are an EU-citizen and would like to support the petition, you can do so by sending an email to the EMA to co-sign the petition
To: email@example.com; petitionEMA@corona-ausschuss.com
Subject: Co-signing the petition of Dr. Wodarg, Germany, and Dr. Yeadon,
UK (submitted on 1-Dec-2020)
Dear Sir or Madam,
I am hereby co-signing the petition of Dr. Wodarg and
Dr. Yeadon to support their urgent request to stay the Phase III clinical
trial(s) of BNT162b (EudraCT Number 2020-002641-42) and other clinical
trials. The full text of the petition of Dr. Wodarg and Dr. Yeadon can be found
I hereby respectfully request that EMA act on the petition of Dr. Wodarg and
Dr. Yeadon immediately.
Please read our Re-publishing Guidelines.